Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats

Yoshinori Miyahara, Shunsuke Ohnishi, Hiroaki Obata, Kozo Ishino, Shunji Sano, Hidezo Mori, Kenji Kangawa, Soichiro Kitamura, Noritoshi Nagaya

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Beraprost sodium, an orally active prostacyclin analogue, has vasoprotective effects such as vasodilation and antiplatelet activities. We investigated the therapeutic potential of beraprost for myocardial ischemia. Immediately after coronary ligation of Sprague-Dawley rats, beraprost (200 μg/kg/day) or saline was subcutaneously administered for 28 days. Four weeks after coronary ligation, administration of beraprost increased capillary density in ischemic myocardium, decreased infarct size, and improved cardiac function in rats with myocardial infarction. Beraprost markedly increased the number of CD34-positive cells and c-kit-positive cells in plasma. Also, four weeks after coronary ligation of chimeric rats with GFP-expressing bone marrow, bone marrow-derived cells were incorporated into the infarcted region and its border zone. Treatment with beraprost increased the number of GFP/von Willebrand factor-double-positive cells in the ischemic myocardium. These results suggest that beraprost has beneficial effects on ischemic myocardium partly by its ability to enhance neovascularization in ischemic myocardium by mobilizing bone marrow cells.

Original languageEnglish
Pages (from-to)1242-1249
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume349
Issue number4
DOIs
Publication statusPublished - Nov 3 2006

Fingerprint

beraprost
Bone Marrow Cells
Rats
Myocardium
Bone
Cells
Ligation
von Willebrand Factor
Epoprostenol
Plasma Cells
Vasodilation
Myocardial Ischemia
Sprague Dawley Rats

Keywords

  • Bone marrow mobilization
  • Myocardial infarction
  • Neovascularization
  • Prostacyclin analogue

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats. / Miyahara, Yoshinori; Ohnishi, Shunsuke; Obata, Hiroaki; Ishino, Kozo; Sano, Shunji; Mori, Hidezo; Kangawa, Kenji; Kitamura, Soichiro; Nagaya, Noritoshi.

In: Biochemical and Biophysical Research Communications, Vol. 349, No. 4, 03.11.2006, p. 1242-1249.

Research output: Contribution to journalArticle

Miyahara, Y, Ohnishi, S, Obata, H, Ishino, K, Sano, S, Mori, H, Kangawa, K, Kitamura, S & Nagaya, N 2006, 'Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats', Biochemical and Biophysical Research Communications, vol. 349, no. 4, pp. 1242-1249. https://doi.org/10.1016/j.bbrc.2006.08.178
Miyahara, Yoshinori ; Ohnishi, Shunsuke ; Obata, Hiroaki ; Ishino, Kozo ; Sano, Shunji ; Mori, Hidezo ; Kangawa, Kenji ; Kitamura, Soichiro ; Nagaya, Noritoshi. / Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats. In: Biochemical and Biophysical Research Communications. 2006 ; Vol. 349, No. 4. pp. 1242-1249.
@article{c7a140a0b3d34e4ea68b53e03062bf66,
title = "Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats",
abstract = "Beraprost sodium, an orally active prostacyclin analogue, has vasoprotective effects such as vasodilation and antiplatelet activities. We investigated the therapeutic potential of beraprost for myocardial ischemia. Immediately after coronary ligation of Sprague-Dawley rats, beraprost (200 μg/kg/day) or saline was subcutaneously administered for 28 days. Four weeks after coronary ligation, administration of beraprost increased capillary density in ischemic myocardium, decreased infarct size, and improved cardiac function in rats with myocardial infarction. Beraprost markedly increased the number of CD34-positive cells and c-kit-positive cells in plasma. Also, four weeks after coronary ligation of chimeric rats with GFP-expressing bone marrow, bone marrow-derived cells were incorporated into the infarcted region and its border zone. Treatment with beraprost increased the number of GFP/von Willebrand factor-double-positive cells in the ischemic myocardium. These results suggest that beraprost has beneficial effects on ischemic myocardium partly by its ability to enhance neovascularization in ischemic myocardium by mobilizing bone marrow cells.",
keywords = "Bone marrow mobilization, Myocardial infarction, Neovascularization, Prostacyclin analogue",
author = "Yoshinori Miyahara and Shunsuke Ohnishi and Hiroaki Obata and Kozo Ishino and Shunji Sano and Hidezo Mori and Kenji Kangawa and Soichiro Kitamura and Noritoshi Nagaya",
year = "2006",
month = "11",
day = "3",
doi = "10.1016/j.bbrc.2006.08.178",
language = "English",
volume = "349",
pages = "1242--1249",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats

AU - Miyahara, Yoshinori

AU - Ohnishi, Shunsuke

AU - Obata, Hiroaki

AU - Ishino, Kozo

AU - Sano, Shunji

AU - Mori, Hidezo

AU - Kangawa, Kenji

AU - Kitamura, Soichiro

AU - Nagaya, Noritoshi

PY - 2006/11/3

Y1 - 2006/11/3

N2 - Beraprost sodium, an orally active prostacyclin analogue, has vasoprotective effects such as vasodilation and antiplatelet activities. We investigated the therapeutic potential of beraprost for myocardial ischemia. Immediately after coronary ligation of Sprague-Dawley rats, beraprost (200 μg/kg/day) or saline was subcutaneously administered for 28 days. Four weeks after coronary ligation, administration of beraprost increased capillary density in ischemic myocardium, decreased infarct size, and improved cardiac function in rats with myocardial infarction. Beraprost markedly increased the number of CD34-positive cells and c-kit-positive cells in plasma. Also, four weeks after coronary ligation of chimeric rats with GFP-expressing bone marrow, bone marrow-derived cells were incorporated into the infarcted region and its border zone. Treatment with beraprost increased the number of GFP/von Willebrand factor-double-positive cells in the ischemic myocardium. These results suggest that beraprost has beneficial effects on ischemic myocardium partly by its ability to enhance neovascularization in ischemic myocardium by mobilizing bone marrow cells.

AB - Beraprost sodium, an orally active prostacyclin analogue, has vasoprotective effects such as vasodilation and antiplatelet activities. We investigated the therapeutic potential of beraprost for myocardial ischemia. Immediately after coronary ligation of Sprague-Dawley rats, beraprost (200 μg/kg/day) or saline was subcutaneously administered for 28 days. Four weeks after coronary ligation, administration of beraprost increased capillary density in ischemic myocardium, decreased infarct size, and improved cardiac function in rats with myocardial infarction. Beraprost markedly increased the number of CD34-positive cells and c-kit-positive cells in plasma. Also, four weeks after coronary ligation of chimeric rats with GFP-expressing bone marrow, bone marrow-derived cells were incorporated into the infarcted region and its border zone. Treatment with beraprost increased the number of GFP/von Willebrand factor-double-positive cells in the ischemic myocardium. These results suggest that beraprost has beneficial effects on ischemic myocardium partly by its ability to enhance neovascularization in ischemic myocardium by mobilizing bone marrow cells.

KW - Bone marrow mobilization

KW - Myocardial infarction

KW - Neovascularization

KW - Prostacyclin analogue

UR - http://www.scopus.com/inward/record.url?scp=33748850756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748850756&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2006.08.178

DO - 10.1016/j.bbrc.2006.08.178

M3 - Article

C2 - 16978584

AN - SCOPUS:33748850756

VL - 349

SP - 1242

EP - 1249

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -